Entera Bio (ENTX) Current Deferred Revenue (2018 - 2021)

Entera Bio has disclosed Current Deferred Revenue across 3 years of filings, most recently posting $15000.0 for Q4 2021.

• Quarterly Current Deferred Revenue fell 90.51% year-over-year to $15000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $15000.0 (down 90.51% YoY) and the FY2021 annual result came in at $15000.0, down 90.51% from the prior year.
• Current Deferred Revenue fell to $15000.0 in Q4 2021, from $158000.0 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $225000.0 in Q4 2018 and troughed at $15000.0 in Q4 2021.
• A 3-year average of $132666.7 and a median of $158000.0 in 2020 frame the typical range for Current Deferred Revenue.
• Biggest YoY gain for Current Deferred Revenue was 90.51% in 2021; the steepest drop was 90.51% in 2021.
• Tracing ENTX's Current Deferred Revenue over 3 years: stood at $225000.0 in 2018, then slipped by 29.78% to $158000.0 in 2020, then plunged by 90.51% to $15000.0 in 2021.
• Business Quant data shows ENTX's Current Deferred Revenue at $15000.0 in Q4 2021, $158000.0 in Q4 2020, and $225000.0 in Q4 2018.